- Home
- NXGL vs LSTA Comparison
NXGL vs LSTA Comparison
Compare NXGL & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXGL
- LSTA
- Stock Information
- Founded
- NXGL 1997
- LSTA 1980
- Country
- NXGL United States
- LSTA United States
- Employees
- NXGL N/A
- LSTA 26
- Industry
- NXGL Medical/Dental Instruments
- LSTA Misc Health and Biotechnology Services
- Sector
- NXGL Health Care
- LSTA Health Care
- Exchange
- NXGL Nasdaq
- LSTA Nasdaq
- Market Cap
- NXGL 19.7M
- LSTA 23.1M
- IPO Year
- NXGL 2021
- LSTA N/A
- Fundamental
- Price
- NXGL $2.36
- LSTA $2.69
- Analyst Decision
- NXGL
- LSTA Strong Buy
- Analyst Count
- NXGL 0
- LSTA 2
- Target Price
- NXGL N/A
- LSTA $23.50
- AVG Volume (30 Days)
- NXGL 35.9K
- LSTA 56.6K
- Earning Date
- NXGL 08-13-2025
- LSTA 08-11-2025
- Dividend Yield
- NXGL N/A
- LSTA N/A
- EPS Growth
- NXGL N/A
- LSTA N/A
- EPS
- NXGL N/A
- LSTA N/A
- Revenue
- NXGL $10,228,000.00
- LSTA $1,000,000.00
- Revenue This Year
- NXGL $52.35
- LSTA N/A
- Revenue Next Year
- NXGL $42.38
- LSTA N/A
- P/E Ratio
- NXGL N/A
- LSTA N/A
- Revenue Growth
- NXGL 116.01
- LSTA N/A
- 52 Week Low
- NXGL $2.10
- LSTA $1.87
- 52 Week High
- NXGL $5.10
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- NXGL 42.79
- LSTA 52.66
- Support Level
- NXGL $2.26
- LSTA $2.45
- Resistance Level
- NXGL $2.58
- LSTA $2.74
- Average True Range (ATR)
- NXGL 0.17
- LSTA 0.27
- MACD
- NXGL -0.03
- LSTA -0.00
- Stochastic Oscillator
- NXGL 18.25
- LSTA 51.81
About NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.